ArticleJPGN reports2025
Multicenter study of continuing ustekinumab after intravenous induction reactions in pediatric Crohn's disease.
Article in JPGN reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactions to intravenous ustekinumab for inflammatory bowel disease (IBD) occur, the frequency of which is uncertain. It is unclear how often subcutaneous treatment is continued after reactions to the intravenous dose, or how well it is tolerated. We therefore conducted a retrospective cohort study of pediatric patients who initiated ustekinumab for Crohn's disease from 6 pediatric IBD centers in the United States. Ten of 207 (5%) patients had an infusion reaction to their induction ustekinumab dose. Of these, 6 (60%) restarted their infusion, five completed the infusion. Subsequently, eight patients were treated with subcutaneous ustekinumab, none of whom develop reactions. Reaction to intravenous induction ustekinumab occurs in 5% of patients. Subcutaneous ustekinumab is generally well tolerated after intravenous reaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.